Dr. Raabe and his team at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University is focused on finding drugs that partner with ONC201 to kill DIPG tumor cells.
The team at MD Anderson is using the Delta-24-GREAT virus to identify weaknesses in DIPG tumors so they can identify and kill the tumor cells.
Dr. Reinberg is identifying a mutation called H3K36me2 that occurs in DIPG cells to illicit immune responses and testing compounds that prevent this mutation from binding to cells.
The Crazy 8 Initiative prioritizes curing the incurable – finding novel targets, drugging un-druggable drivers of pediatric cancer, examining the developmental origins of pediatric cancer, and developing effective immunotherapies for hard to cure cancers.
Our latest research initatives are giving 16 Children and Families a Chance For Life
Chance for Life’s clinical T-Cell trial called ReMIND focuses on retraining a child’s T-Cells to identify and destroy cancer cells. The trial has enrolled 16 participants and is showing promising results.
Doctors first identified more than 200 proteins then prioritized 45 fragments of the proteins found in medulloblastoma tumors, the most common malignant pediatric brain tumor. These proteins, not found in healthy tissues, are promising immunotherapy targets.
Liquid biopsy is emerging as a platform for rapid identification of tumor-associated gene alterations. Through this, doctors can profile a tumor’s type, examine its response to treatment and potentially detect a recurrence while avoiding invasive and damaging surgical biopsies.
With ALSF, Chance for Life has funded researchers at Stanford and Johns Hopkins to create spinal cord tumor models growing human cancers, in order to monitor how they grow and the pharmaceutical impact. Another Chance for Life funded project involves 3-D printing synthetic bone grafts to replace bone removed from osteosarcoma and spinal cord tumor patients. This method has proven to be a safe and more effective option than in-patient treatment/testing.
Chance for Life is currently supporting a revolutionary CAR T-Cell trial named GINAKIT2. This first-in-human study of CAR NKT cells seeks to find the maximum safe dose of GD2-CAR NKT cells, evaluate the engineered cells effect on a cancerous tumor, determine how long the cells can be detected in the patient's blood and understand what affect they have on the patient's tumor.